Boston-based Scott Rocklage has developed a unique life mission. He works with entrepreneurs, Business, and Medical Executives to help them turn their ideas into potential medicines to serve needs that are currently not met. He’s excited for the future in the biosciences field, especially in areas, especially in targeting specific mutations and genotypes to treat cancer in new ways, and saving lives.
Dr. Rocklage’s day doesn’t fall into mundane ruts as he’s always studying new areas of life science, in addition to working with various Management Teams and Board Members, turning bioscience ideas into reality.
Dr. Rocklage joined Life Sciences Investment Firm 5AM in 2003 as a Venture Partner, becoming Managing Partner in 2004. The firm focuses on building next generation life science companies with the potential to drive home substantial returns. Learn more about Patty Rocklage: http://www.rennovia.com/team/scott-m-rocklage/ and http://5amventures.com/team/scott-m-rocklage-phd/
Here, Rocklage uses his three decades in healthcare management to make ideas come to life. His leadership also led to FDA approval of three U.S. New Drug Applications Cubicin, Omniscan, and Teslascan as well as entering several drug candidates into clinical trials.
In the past, Dr. Rocklage has also served as President and CEO of Nycomed Salutar, and CEO and Chairman of Cubist Pharmaceuticals. Additionally, he has held various Research and Development positions at Catalytica and Salutar. He has also served as Board Chairman of Relypsa and Novira, which was acquired by Johnson & Johnson.
Dr. Rocklage currently serves as Board Chairman of Kinestral Rennovia, Cidara, and the Boards of Pulmatrix and Epirus. He was formerly Executive Chairman of Ilypsa which was acquired by Amgen, Miikana, acquired by EntreMed, and Semprus, acquired by Teleflex.
Dr. Rocklage holds a Bachelor of Science in Chemistry from the University of California, Berkeley and earned his PhD in Chemistry from the Massachusetts Institute of Technology. Over the years, Dr. Rocklage has been responsible for more than thirty U.S. patents and over 100 peer-reviewed publications.